Key Takeaways
- •EMR underreports tobacco; comprehensive screening essential.
- •CPT 99406 can be billed up to eight times yearly.
- •Varenicline outperforms other meds, affordable via Cost Plus.
- •Scheduled follow‑up doubles cessation effectiveness.
- •Integrate mental‑health referrals for patients with mood disorders.
Summary
Dr. Edward Anselm warns that tobacco cessation remains inconsistently delivered despite being a low‑cost, high‑impact intervention for the 28 million U.S. smokers. He outlines a systematic approach: accurate EMR screening, routine quit advice, evidence‑based medication (notably varenicline), counseling, scheduled follow‑ups, and integration of mental‑health support. The article stresses billing opportunities (CPT 99406) and the financial upside of treating tobacco use like hypertension or diabetes. Measuring performance and adopting workflow changes are presented as the final, organizational steps needed to close the treatment gap.
Pulse Analysis
Tobacco use remains the leading preventable cause of death in the United States, yet clinicians treat it far less consistently than chronic conditions such as hypertension or diabetes. Electronic health records often miss or misclassify patients’ tobacco status, creating a blind spot that prevents timely intervention. By adopting standardized screening protocols—mirroring best practices from health systems like Kaiser Permanente—providers can capture every user, turning a simple question into a powerful catalyst for change.
Evidence shows that brief counseling, when combined with FDA‑approved medications, dramatically raises quit rates. Varenicline, for example, delivers roughly 50% greater success than other pharmacotherapies and is now available at low cost through programs like Cost Plus Drugs. Moreover, clinicians can bill CPT 99406 for three‑minute counseling sessions up to eight times per year, turning a routine encounter into a reimbursable service. In value‑based payment models, the downstream savings from reduced hospitalizations and chronic disease management further justify investing in systematic cessation pathways.
Operationalizing these recommendations requires workflow redesign: EMR prompts for tobacco status, delegation of counseling to trained staff, and scheduled follow‑up contacts that can double intervention effectiveness. Integrating behavioral health resources addresses the high prevalence of nicotine use among patients with mood disorders, while harm‑reduction options such as FDA‑approved vaping products offer alternatives for those unable to quit outright. By tracking metrics, calculating economic impact, and aligning incentives, health systems can elevate tobacco treatment to the same priority level as other chronic diseases, ultimately improving population health and financial performance.
Comments
Want to join the conversation?